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Decades of research went into understanding the role that Th1 autoreactive T-cells play in neuroinﬂammation. Here we describe
another eﬀector population, the IL-17-producing T-helper lineage (Th17), which drives the inﬂammatory process. Through the
recruitment of inﬂammatory inﬁltration neutrophils and the activation of matrix metalloproteinases, IL-17, a cytokine secreted
by Th17 cells, contributes to blood-brain barrier breakdown and the subsequent attraction of macrophages and monocytes into
the nervous system. The entry of cells along with the local production of inﬂammatory cytokines leads to myelin and axonal
damage. This activation of the inﬂammatory response system is induced by diﬀerent pathogenic factors, such as gut bacterial
endotoxinsresultinginprogressiveneurodegenerationbyTh17cells.Throughtheunderstandingoftheroleofbacterialendotoxins
and other pathogenic factors in the induction of autoimmune diseases by Th17 cells, CAM practitioners will be able to design
CAM therapies targeting IL-17 activity. Targeted therapy can restore the integrity of the intestinal and blood-brain barriers using
probiotics, N-acetyl-cysteine, α-lipoic acid, resveratrol and others for their patients with autoimmunities, in particular those with
neuroinﬂammationand neurodegeneration.
1.Introduction
In the previous article, we established the diﬀerentiation
of activated T-helper cells into T-helper-17 (Th17) and the
pathogenic role of interleukin-17 (IL-17) in neuroimmune
disorders.Herewereviewtheinﬂammatory pathophysiology
of intestinal barrier permeability, which can lead to the
breach of the blood-brain barrier (BBB). The tight junctions
of the intestinal barrier may open due to environmen-
tal stressors, which can upset the microﬂora homeostasis
therebyproducingendotoxinsthatactivate proinﬂammatory
cytokine IL-1β. The upregulation of IL-1β begins a cascade
of the inﬂammatory response system, resulting in high levels
of IL-17-producing cells in various tissues. Additionally,
the stressors that are capable of opening the epithelial
tight junction barrier are also able to breakdown the BBB.
Once inside the central nervous system, Th17 deposits IL-
17 leading to CNS inﬂammation, which attracts additional
inﬂammatory substances [1–6]. Neuropeptide substance P
(SP), along with its high aﬃnity receptor neurokinin-1 (NK-
1), activates NF-κB, a facilitator in the production of proin-
ﬂammatory cytokines,and SPalso reducesthe productionof
immunoregulatory IL-10 and TGF-β [7–9]. Therefore, daily
environmental stressors can disrupt gut function, which can
lead to breakdown of the BBB and subsequent induction
of neuro-inﬂammation. Our objective is to provide CAM
practitioners with additional targets in the assessment and
treatment of patients presenting with autoimmune, inﬂam-
matory or neuroimmune disorders. Therapeutic protocols
may include integrative use of pharmaceuticals in conjunc-
tion with CAM therapies entailing body, mind and spirit,
for the repair of gut barrier dysfunction ﬁrst, systemic




Environmental factors such as stress, drugs and xenobiotics
can induce imbalanced gut ﬂoral and bacterial transloca-
tion. These stressors mediate intestinal permeability with
subsequent development of intestinal inﬂammation [1, 2].






















































Figure 1: Proposed scheme of the induction by environmental factors of mucosal immune dysregulation and the production of
inﬂammatorycytokines, resulting in the epithelial cell tight junction opening and the entry of bacterial and food antigens in the circulation
and further activation of inﬂammatory cascade in the blood and in diﬀerent tissues. CAM targets may include one or a combination of the
following:inhibition of proinﬂammatory cytokines, inhibition of IL-1β binding to its receptor and inhibition of NF-κBa c t i v a t i o n .
preparedfromenteropathogenicEscherichia coli,Clostridium
diﬃcile, Klebsiella pneumoniae, Pseudomonas aeruginosa,
Hafnia alvei, Citrobacter koseri and others, can induce an
increase in intestinal tight junction (TJ) permeability [3–5].
Imbalanced gut ﬂora can result in the production of LPS
by a variety of gram-negative bacteria. The release of LPS
induces mucosal immune dysregulation and the production
of proinﬂammatory cytokines, in particular IL-1β,I L - 6a n d
TNF-α [6].
IL-1β production induced by LPS can promote inﬂam-
matory response in various tissues [6, 10–12]. This enhanced
productionof IL-1β causes direct disruption of the intestinal
TJ barrier leading to paracellular permeation of luminal
antigens into circulation, which may contribute to sys-
temic inﬂammation [13–17]. Until recently, the intracellular
mechanism that mediates IL-1β modulation of intestinal TJ
barrier was not clear [18]; therefore, several studies tried to
elucidate this mechanism of action [19–21].
Previously it was shown that IL-1β causes an increase
in NF-κB activation, which was required for IL-1β-induced
increase in TJ permeability [13]. In their recent article [18],
Al-Sadi and colleagues indicate that IL-1β causes a rapid
activation of NF-κB and inhibition of NF-κBa c t i v a t i o n
prevented IL-1β-induced MLCK protein expression and TJ
permeability. These ﬁndings indicate that NF-κBa c t i v a t i o n
of TJ barrier is mediated in part by an increase in MLCK
protein and mRNA expression [18]. To further identify the
role of NF-κBinm ediatin gIL - 1β-induced MLCK expression
and TJ permeability, researchers used NF-κBP 6 5s i l e n c i n g
studies using SiRNA. The SiRNA silencing of NF-κBP 6 5
expression completely inhibited the IL-1β-induced protein
expression and its drop in transepithelial electrical resistance
of intestinal monolayers, which conﬁrmed the regulatory
role of NF-κBi nt h em e d i a t i o no fI L - 1 β-induced MLCK
mRNA transcription and protein expressions [22]. IL-1β
binding to IL-1β receptor on epithelial cells causes a rapid
activation of NF-κB, IκB-α phosphorylation and IκB-α
degradation. NF-κB activation leads to its translocation into
the nucleus, resulting in stimulation of myosin L-chain
kinase activation, increase in myosin L-chain kinase (MLCK)
RNA and MLC kinase synthesis [22–26]. This increase in
MLCK activity leads to the opening of TJ barriers and the
entry of bacterial endotoxins (LPS), and dietary proteins
and peptides into the submucosa, regional lymph nodes and
blood stream, followed by the initiation of inﬂammation in
circulation and in diﬀerent tissues (Figure 1).
The understanding ofcellular mechanisms, which leadto
intestinal TJ barrier defect during inﬂammatory conditions,
can assist in designing potential CAM therapeutic interven-
tions targeting IL-1β NF-κBor othermoleculesnecessary for




Recently, it was shown that intestinal barrier dysfunction,
with an increased translocation of LPS, correlated withEvidence-Based Complementary and Alternative Medicine 3
serum IgA and IgM against LPS and the inﬂammatory
pathophysiologyofdepressionandchronicfatiguesyndrome
[27, 28]. Normalization of increased LPS translocation is
accompanied by a remission in clinical symptomatologies.
Therefore, the regulation of intestinal barrier function via
CAM therapies such as yoga, herbal cleanses and use of
probiotics, is proven to be an important ﬁrst step in the
recovery of patient health.
4.The Effectof LPSand Inﬂammatory
C ytokinesontheI nductionofBBB
Disruptionand Neuroinﬂammation
The BBB separates blood leukocytes, which normally
respond tonecroticinjury, from the brain parenchyma where
necrotic cell death might take place in response to envi-
ronmental factors such as infections, toxins, excitotoxicity
or trauma [24]. The BBB is composed of two layers. The
ﬁrst layer consists of microvascular endothelial cells, which
have abundant tight junctions with structural similarity to
that of intestinal epithelial cells [27]. The second layer is
the glia limitans, which is formed by glial foot processes
[26]. The perivascular space between the endothelial cells
and astrocytes is populated by macrophages, which behave
like immature dendritic cells [26]. Therefore, factors capable
of opening the epithelial TJ barrier are able to destroy both
the BBB and neural tissue [27–30]. This includes bacterial
endotoxins,proinﬂammatory cytokines,enzyme andeﬀector
cellsTh1 andTh17,which areessential tothecentralnervous
system inﬂammation [27–31].
It is ﬁrmly established that disruption of the BBB by
endotoxins, cytokines, chemokines, adhesion molecules and
others, and the traﬃcking of autoreactive T-cells from the
systemic compartment into the central nervous system play
an important role in the development of MS lesions [32–
34].However,whenacomparisonwasmadebetweenhuman
T h 1v e r s u sT h 1 7l y m p h o c y t e s ,h u m a nT h 1 7l y m p h o c y t e
migrated faster across the BBB than Th1 lymphocytes.
Indeed a signiﬁcant number of IL-17- and IL-22-expressing
CD4+CD45RO+ memory lymphocytes upon their migration
across BBB expressed IL-17+ and IL-22+ markers, which
conﬁrmed the ability of Th17 lymphocytes to cross the BBB
in vitro and in vivo [31]. The BBB endothelial cells expressed
IL-17R and IL-22R, which are used by Th17 lymphocytes
to inﬁltrate the BBB endothelial cells (ECS). This diﬀusion
of cells or antigens, such as bovine serum albumin (BSA),
across the BBB was enhanced signiﬁcantly when IL-17
and IL-22 were added to monolayers of human BBB-ECS.
This enhanced permeability of BBB-ECS correlated with a
decrease in the expression of occludin and zonulin, the two
important tight junction proteins [35].
To validate observations of Th17 involvement under
human neuroinﬂammatory conditions, brain sections from
humans with MS and from unaﬀected controls were
immunostained for IL-17, IL-22 and CD45RO. Many
CD45RO+ cells immunopositive for IL-17 or IL-22 were
shown in patients with MS but not in controls [31]. These
results emphasized the importance of Th17 inﬁltration into
the CNS for the development of brain lesions in MS. In
a search for a mechanism of lesion induction by Th17 cells
in MS, it was shown that in addition to IL-17 production
and its proinﬂammatory action, up to 60% of cells express-
ing IL-17 and also IL-22 expressed the cytolytic enzyme
c a l l e dg r a n z y m eB .F u r t h e r m o r e ,w h e ng r a n z y m eB - T h 1 7
cells were added to neuron-enriched cultures, a signiﬁcant
number of neurons underwent programed cell death [31–
34]. Therefore, Th17 cell production of mediators such as
granzyme B contributes to their highly encephalitogenecity.
Since microglia plays a signiﬁcant role in MS, to fur-
ther strengthen the role of IL-17 in CNS inﬂammation,
microglia were treated with IL-17. Treatment with IL-17
upregulated the microglial production of IL-6, MIP-2, nitric
oxide, adhesion molecules and neurotrophic factors [35–
39]. It was also found that IL-17 could be produced by
microglia in response to IL-1β or IL-23. Because microglia
produces IL-1β and IL-23, these cytokines may act in an
autocrine manner to express IL-17 on microglia, and thereby
contribute to autoimmune disease in the CNS [39]. These
results strongly suggest that the cells co-expressing IL-17,
IL-22 and granzyme B through the action of IL-17 and IL-
22 play a signiﬁcant role in the induction and breach in
the BBB and the permeabilization of BBB to circulating
CD4+ lymphocytes and soluble molecules resulting in CNS
inﬂammation [37]. The role of Th17 lymphocytes in the
pathogenesis of inﬂammatory and neuroimmunological
disorders is shown in Figure 2. This role of Th17 cells and
the IL-17 produced by them in neuroinﬂammation make
these novel CD4 cells a suitable target for CAM treatment of
neuroimmune disorders that aﬀect a signiﬁcant percentage
of the population. Steps to tackling neuroinﬂammation
begin with the repair of gastrointestinal barrier dysfunction,
followed by dampening systemic inﬂammation and ending
with the restoration of the BBB.
5.Direct EffectofBacterialAntigenson
theProductionofIL-17and Other Cytokines
by Microglia and Astrocytes
It has become increasingly apparent that resident glial cells
such as microglia and astrocytes, play an important role
in the initiation and progression of immune responses
following pathogen invasion or their antigens [40–42]. Such
infections are associated with high levels of inﬂammatory
cytokines including IL-1β,I L - 6 ,T N F - α and IL-17 in the
CNS that result in neurological dysfunction. Microglia and
astrocytes can perceive bacteria through microbial pattern
recognition receptors, such as TLR and nucleotide-binding
domain leucine-rich repeat containing receptor families.
Binding of bacteria to these receptors promotes recruitment
and antigen-speciﬁc activation of inﬁltrating leukocytes [42,
43].
A compelling body of evidence has accumulated in the
literature to show that substance P (SP) plays an important
roleintheaugmentationofinﬂammatory immuneresponses
in the gastrointestinal tract, the skin and other peripheral
sites [7, 8]. Neuropeptide SP can also modulate the function
of myeloid cells, such as dendritic cells and macrophages
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Recruitment of autoreactive T
cells and CNS inﬂammation
Figure 2: The role of Th17 lymphocytes in the pathogenesis of inﬂammatory and neuroimmunological disorders. Environmental factors’
induction of inﬂammatoryresponse, production of cytokines and increase in the number of Th17 positive cells in circulation. Expressionof
IL-17 andIL-22 receptors onblood-brain barrier endothelial cells result inthe bindingofTh17 cells to BBB tightjunctions.This disrupts the
tight junctions, and the Th17 cells then transmigrate across the BBB, setting the stage for the killing of neurons by the release of granzyme
B. CAM protocols may be used to block the inﬂammatory cascade induced by infection. Additionally, CAM therapies resulting in the repair
of the BBB and the inhibition of lymphocyte transmigration can reduce neuro-inﬂammation.
interestingly, both bacterial antigens LPS and SP with NK-
1R activate the transcription factor NF-κB, which facilitates
the production of key proinﬂammatory cytokines such as
TNF-α, IL-6 and IL-17. Furthermore, SP can reduce the
production of immunoregulatory cytokines (TGF-β, IL-10)
by macrophages, thereby further exacerbating inﬂammation
[7, 8].
The most abundant tachykinin in the brain, SP, with
its high aﬃnity receptor NK-1R is expressed on microglia,
which shares a common myeloid lineage with macrophages
and dendritic cells [9]. Furthermore, it was shown that
SP can synergistically augment Borrelia burgdorferi-induced
expression of cyclooxygenase-2 in microglia and increased
secretion of inﬂammatory prostanoid PGE2 [44]. Recently
Chauhan and colleagues [45]d e m o n s t r a t e dt h a tS P ,i n
addition to PGE2, augments production of inﬂammatory
cytokines by microglia and astrocytes following exposure to
clinically relevant bacterial CNS pathogens such as Neisseria
meningitides and B. burgdorferi. Taken together, these studies
indicate a potentially important role for neuropeptide SP in
the exacerbation of the resident glial immune response dur-
ing inﬂammatory CNS disorders induced by infections, such
as B. burgdorferi [46]. The mechanism by which bacterial
antigens, through the production of SP by neurons and their
binding to SP receptors, result in cytokine production and
CNS inﬂammation is shown in Figure 3.F u r t h e r m o r e ,t h e
ability of CAM treatment with products, such as SP receptor
antagonist for the inhibition of NF-κB, or minocycline [47,
48], α-Lipoic acid [49], resveratrol [50]o rq u e r c e t i n[ 51]
which are shown tobe eﬀectiveintherepair ofBBBdamaged
by infections, may represent important new therapeutic
strategies to combat potentially disabling consequences of
inﬂammation within the brain.
Such an approach was described earlier in eCAM Journal
under the title of “Novel diagnosis of Lyme disease: potential
forCAMintervention.”Thisarticledescribedthemechanism
by which B. burgdorferi induces inﬂammation by enhancing
proinﬂammatory cytokine production, activation of matrix
metalloproeinases resulting in BBB damage and chronic
neuroborreliosis [46]. The article concluded that “practi-
tioners of complementary and alternative medicine (CAM)
by utilization of this analytical method will increase the
accuracy of the diagnostic process and abridge the time for
treatment with antibiotics, herbal medicines and nutritional
supplements, resulting in improved quality of care and
disease prognosis.” This approach using CAM treatment
for many neuroimmune and autoimmune diseases of the
CNS that start in the GI tract and manifest themselves in
various tissues is further discussed in this and Part III of this
article.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Direct eﬀect of bacterial antigens (LPS) on the production of substance P and its exacerbation of the early inﬂammatory response
to neural cell antigens. CAM inhibition of NF-κB activation by microglia, astrocytes and macrophages may result in reduced neural cell
damage.
6.Conclusion
Although the assessment of Th1 and Th2 cytokines is used
as a guide for intervention by some CAM practitioners in
implementingtherapeuticinterventions,itistheT-helper-17
producing IL-17 which has emerged as the most pathogenic
helper cell meriting possible CAM intervention. Beginning
withIL-1β-induced inﬂammation ofthegut,TJ permeability
is brought on by the activation of MLCK phosphorylation
of myosin L-chain, which in turn causes the contraction
of peri-junctional actin-myosin ﬁlaments and the opening
of intestinal barriers. Bacterial endotoxins, proinﬂammatory
cytokines, enzymes and eﬀector cells Th1 and Th17 are also
capable of disrupting the BBB, inducing inﬂammation in
the central nervous system. Inside the CNS, neuropeptide
SP, along with NK-1R, is expressed on microglia and can
modulatethefunction ofmyeloid cells.BothSPwith NK-1R,
and LPS activate NF-κB, which facilitates the production of
proinﬂammatory cytokines, notably IL-6, IL-17 and TNF-α.
Inadditiontoexacerbating inﬂammation, SPcanalso reduce
the production of regulatory cytokines such as IL-10 and
TGF-β.E ﬀective treatment of inﬂammatory disorders in the
gutandthenervoussystemrequiresﬁrst anunderstandingof
the aﬀect of cytokines on the cells and tissues around them,
and second the maintenance of the delicate balance between
pro-, anti- and regulatory cytokines. The measurement of
multiple cytokines will present the CAM practitioner with
a broader picture of the patient’s inﬂammatory condition,
and thereby would be useful in ﬁtting a therapeutic inter-
vention on an individual basis. As seen above, for cases of
neuroimmune disorders, the modulation of IL-17, IL-6, IL-
1β,S Pa n dN F - κB, the therapeutic support of the intestinal
barrier and BBB repair are becoming important targets for
CAMpractitioners. Details on an array of anti-inﬂammatory
medications, ranging from pharmaceuticals to vitamins and
from botanicals to innate molecules, are discussed in Part III
of this article.
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